Beauty industry insiders have brought allegations concerning exclusivity commitments to LEADERMAGAZIN’s attention. Our ongoing journalistic investigation examines what commercial partners were promised, whether those commitments were honoured and what evidence supports the accounts received.
An exclusive agreement can determine whether a business invests in a manufacturer’s products. Demonstration equipment, staff training and local marketing all require resources. For a distributor or beauty business, the promise of a protected territory may be central to that decision.
Beauty industry insiders who have approached LEADERMAGAZIN allege that exclusivity commitments associated with Cesare Quaranta’s business were not respected. The accounts concern commercial relationships in the DACH region—Germany, Austria and Switzerland—as well as Spain and France.
These are allegations under examination. They do not establish that every agreement was breached or that the circumstances were identical across different markets. Our journalistic investigation is ongoing.
Written Commitments and Actual Sales Practices
The central issue is the relationship between contractual promises and subsequent business activity. What protection was granted, to whom, and subject to which conditions?
The insiders’ accounts raise questions about whether additional suppliers or commercial partners operated in territories where exclusivity had previously been promised. Establishing a breach requires more than identifying another business offering the same equipment.
The relevant agreement must specify the products, territory, duration and any conditions attached to exclusivity. Minimum purchase requirements, reserved customers, direct-sales provisions and subsequent amendments may materially affect the assessment.
The investigation must also establish the manufacturer’s involvement in each disputed transaction. Equipment reaching a territory through an independent resale is not necessarily equivalent to a manufacturer appointing an additional distributor contrary to an existing commitment.
Accounts From Several European Markets
The accounts brought to LEADERMAGAZIN’s attention extend beyond a single country. That makes comparison worthwhile, but geographical reach alone does not establish a coordinated or repeated practice.
The investigation therefore examines both the allegations and possible alternative explanations. Relevant considerations include whether agreements remained in force, whether purchase commitments were met and whether exceptions had been expressly accepted.
Any eventual findings must distinguish independently corroborated events from statements that remain disputed or unsupported.
Commercial Losses Must Be Demonstrated
The commercial concern is straightforward: a partner who invests on the strength of exclusivity may face unexpected competition before recovering that investment.
Potential consequences include lost orders, reduced margins and expenditure on marketing or demonstrations that no longer produces the anticipated return. Whether those consequences occurred in the relationships under review—and whether they resulted from a contractual breach—requires supporting evidence.
The assessment must identify the transaction or expenditure involved, explain its connection to the alleged conduct and consider other factors affecting business performance.
A Separate Inquiry Into Performance Claims
The company’s website presents its MYA devices as technologies for body contouring and improving the appearance of cellulite. Its presentation also refers to patents and a manufacturing history dating back to 1986.
Questions have additionally been raised during the preparation of this investigation about the substantiation of advertised treatment effects. This is a separate issue from the exclusivity allegations and requires a different evidential assessment.
The inquiry must identify the precise claim, the device model and treatment protocol concerned, and the evidence offered in support. Relevant studies or technical assessments should then be examined for their methodology, scope and applicability, with independent specialist input where necessary.
References to patents should be considered separately from the question of what evidence supports a particular treatment outcome.
The Company’s Explanation Matters
Cesare Quaranta’s account is essential to a fair assessment. The company should have the opportunity to address each sufficiently specified allegation, explain its interpretation of the agreements and provide relevant supporting material.
Our investigation remains open to evidence that supports, qualifies or contradicts the accounts received. Its outcome will depend on verifiable agreements, documented transactions and the explanations of those involved.
LEADERMAGAZIN has contacted Cesare Quaranta for comment on the allegations. At the time of writing, no response had been received. Our journalistic investigation is ongoing.
Wichtiger Hinweis: Die Inhalte dieses Magazins dienen ausschließlich Informations- und Unterhaltungszwecken und besitzen keinen Beratercharakter. Die bereitgestellten Informationen waren zum Zeitpunkt der Veröffentlichung aktuell. Eine Garantie für Vollständigkeit, Aktualität und Richtigkeit wird nicht übernommen, jegliche Haftung im Zusammenhang mit der Nutzung dieser Inhalte ist ausgeschlossen. Diese Inhalte ersetzen keine professionelle juristische, medizinische oder finanzielle Beratung. Bei spezifischen Fragen oder besonderen Umständen sollte stets ein entsprechender Fachexperte hinzugezogen werden. Texte können mithilfe von KI-Systemen erstellt oder unterstützt worden sein.
